Vascular endothelial growth factors and their receptors and regulators in gestational trophoblastic diseases and normal placenta

Journal of Reproductive Medicine

Volumn 57, Issue 5-6, 2012, Pages 197-203

  Singh, Margit ^a,b,c,d   Kindelberger, David ^a,b,c,d   Nagymanyoki, Zoltan ^a,b,c,d   Ng, Shu Wing ^a,b,c,d   Quick, Charles M ^a,b,c,d   Yamamoto, Hidemi ^a,b,c,d   Fichorova, Raina ^a,b,c,d   Fulop, Vilmos ^a,b,c,d   Berkowitz, Ross S ^a,b,c,d  

^a UNIVERSITY OF SZEGED   (Hungary)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c National Health Center   (Hungary)

^d SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

CD147; Gestational trophoblastic disease; IL 6; Interleukin 6; Placenta growth factor; Placental site trophoblastic tumor; Vascular endothelial growth factor receptor; VEGFR 1; VEGFR 2; VEGFR 3

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 2; CD147 ANTIGEN; INTERLEUKIN 6; PLACENTAL GROWTH FACTOR; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; BSG PROTEIN, HUMAN; PLACENTA PROTEIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR;

ARTICLE; CELL LINE; CELL LYSATE; CHORIOCARCINOMA; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYDATIDIFORM MOLE; IMMUNOHISTOCHEMISTRY; IMMUNOLOCALIZATION; IMMUNOREACTIVITY; PLACENTA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUPERNATANT; SYNCYTIOTROPHOBLAST; TROPHOBLASTIC TUMOR; VASCULAR ENDOTHELIUM; CHEMISTRY; FEMALE; PREGNANCY; TUMOR CELL LINE; UTERUS CANCER;

ANGIOPOIETIN-1; ANGIOPOIETIN-2; ANTIGENS, CD147; CELL LINE; CELL LINE, TUMOR; CHORIOCARCINOMA; FEMALE; GESTATIONAL TROPHOBLASTIC DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-6; PLACENTA; PREGNANCY; PREGNANCY PROTEINS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; UTERINE NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3;

EID: 84864106738     PISSN: 00247758     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Horowitz NS, Goldstein DP, Berkowitz RS: Management of gestational trophoblastic neoplasia. Semin Oncol 2009;36: 181-189
2. Hsieh FJ, Wu CC, Lee CN, et al: Vascular patterns of gestational trophoblastic tumors by color Doppler ultrasound. Cancer 1994;74:2361-2365
3. Folkman J, Cole P, Zimmerman S: Tumor behavior in isolated perfused organs: In vitro growth and metastases of biopsy material in rabbit thyroid and canine intestinal segment. Ann Surg 1966;164:491-502
4. Langer R: Control of tumor growth in animals by infusion of an angiogenesis inhibitor. Proc Natl Acad Sci USA 1980;77: 4331-4335
5. Eichhorn ME, Kleespies A, Angele MK, et al: Angiogenesis in cancer: Molecular mechanisms, clinical impact. Langenbecks Arch Surg 2007;392:371-379
6. Ferrara N: Vascular endothelial growth factor: Basic science and clinical progress. Endocr Rev 2004;25:581-611
7. Hicklin DJ, Ellis LM: Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005;1011-1027
8. Carmeliet P, Ferreira V, Breier G, et al: Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996;380:435-439
9. Ferrara N, Carver Moore K, Chen H, et al: Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996;380:439-442
10. Carpini JD, Karam AK, Montgomery L: Vascular endothelial growth factor and its relationship to the prognosis and treatment of breast, ovarian, and cervical cancer. Angiogenesis 2010;13:43-58
11. Köhne CH, Lenz HJ: Chemotherapy with targeted agents for the treatment of metastatic colorectal cancer. Oncologist 2009;14:478-488
12. Subramanian J, Morgensztern D, Govindan R: Vascular endothelial growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Lung Cancer 2010;11:311-319
13. Stuttfeld E, Ballmer-Hofer K: Structure and function of VEGF receptors. IUBMB Life 2009;61:915-922
14. Cao Y: Positive and negative modulation of angiogenesis by VEGFR1 ligands. Sci Signal 2009;2(59):re1
15. Achen MG, Stacker SA: Molecular control of lymphatic metastasis. Ann N Y Acad Sci 2008;1131:225-234
16. Minchenko A, Bauer T, Salceda S, et al: Hypoxic stimulation of vascular endothelial growth factor expression in vitro and in vivo. Laboratory Investigation 1994;71:374-379
17. Wei LH, Kuo ML, Chen CA, et al: Interleukin-6 in cervical cancer: The relationship with vascular endothelial growth factor. Gynecol Oncol 2001;82:49-56
18. Salgado R, Vermeulen PB, Benoy I, et al: Platelet number and interleukin-6 correlate with VEGF but not bFGF serum levels of advanced cancer patients. Br J Cancer 1999;80:892-897
19. Benoy I, Salgado R, Colpaert C, et al: Serum interleukin 6, plasma VEGF, serum VEGF, and VEGF platelet load in breast cancer patients. Clin Breast Cancer 2002;2:311-315
20. Kanekura T, Chen X: CD147/basigin promotes progression of malignant melanoma and other cancers. J Dermatol Sci 2010;57:149-154
21. Bougatef F, Quemener C, Kellouche S, et al: EMMPRIN promotes angiogenesis through hypoxia-inducible factor-2alpha-mediated regulation of soluble VEGF isoforms and their receptor VEGFR-2. Blood 2009;114:5547-5556
22. Nagymanyoki Z, Growdon WB, Sarno J, et al: Vascularization and expression of angiogenic factors in partial and complete molar pregnancies. J Reprod Med 2008;53:589-594
23. Fichorova RN, Richardson-Harman N, Alfano M, et al: Biological and technical variables affecting immunoassay recovery of cytokines from human serum and simulated vaginal fluid: A multicenter study. Analyt Chem 2008;80:4741-4751
24. Clark DE, Smith SK, Licence D, et al: Comparison of expression patterns for placenta growth factor, vascular endothelial growth factor (VEGF), VEGF-B and VEGF-C in the human placenta throughout gestation. J Endocrinol 1998; 159:459-467
25. Whitley GS, Cartwright JE: Cellular and molecular regulation of spiral artery remodeling: Lessons from the cardiovascular field. Placenta 2010;31:465-474
26. Seckl MJ, Sebire NJ, Berkowitz RS: Gestational trophoblastic disease. Lancet 2010;376:717-729
27. Lan C, Li Y, He J, et al: Placental site trophoblastic tumor: Lymphatic spread and possible target markers. Gynecol Oncol 2010;116:430-437
28. Cole ME, Broaddus R, Thaker P, et al: Placental-site trophoblastic tumors: A case of resistant pulmonary metastasis. Nat Clin Pract Oncol 2008;5:171-175
29. Smith NR, Baker D, James NH, et al: Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers. Clin Cancer Res 2010;16:3548-3561
30. Khankin EV, Royle C, Karumanchi SA: Placental vasculature in health and disease. Semin Thromb Hemost 2010;36:309-320
31. Millimaggi D, Mari M, D' Ascenzo S: Vasculogenic mimicry of human ovarian cancer cells: Role of CD147. Int J Oncol 2009;35:1423-1428
32. Ĺukaszewicz M, Mroczko B, Szmitkowski M: Clinical significance of interleukin-6 (IL-6) as a prognostic factor of cancer disease. Pol Arch Med Wewn 2007;117:247-251
33. Sotiriou C, Lacroix M, Lespagnard L, et al: Interleukins-6 and-11 expressions in primary breast cancer and subsequent development of bone metastases. Cancer Lett 2001;169:87-95
34. Duan Z, Ames RY, Ryan M, et al: CDDO-Me, a synthetic triterpenoid, inhibits expression of IL-6 and Stat3 phosphorylation in multi-drug resistant ovarian cancer cells. Cancer Chemother Pharmacol 2009;63:681-689
35. Tabibzadeh SS, Santhanam U, Sehgal PB, et al: Cytokineinduced production of IFN-beta 2/IL-6 by freshly explanted human endometrial stromal cells: Modulation by estradiol-17 beta. J Immunol 1989;142:3134-3139
36. Bischoff J, Ignatov A: The role of targeted agents in the treatment of metastatic breast cancer. Breast Care (Basel) 2010;5: 134-141
37. Murphy JE, Ryan DP: American Society of Clinical Oncology 2010 colorectal update. Expert Rev Anticancer Ther 2010; 10:1371-1373
38. Moreno-Aspitia A: Clinical overview of sorafenib in breast cancer. Future Oncol 2010;6:655-663